Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

M. Dowsett; J. F. Forbes; R. Bradley; J. Ingle; T. Aihara; J. Bliss; F. Boccardo; A. Coates; R. C. Coombes; J. Cuzick; P. Dubsky; M. Gnant; M. Kaufmann; L. Kilburn; F. Perrone; D. Rea; B. Thuerlimann; C. van de Velde; H. Pan; R. Peto; C. Davies; R. Gray; M. Baum; A. Buzdar; I. Sestak; C. Markopoulos; C. Fesl; R. Jakesz; M. Colleoni; R. Gelber; M. Regan; G. von Minckwitz; C. Snowdon; P. Goss; Early Breast Cancer Trailists’ Collaborative Group EBCTCG; Petrus Hupperets

doi:10.1016/S0140-6736(15)61074-1

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

M. Dowsett^*
, J. F. Forbes
, R. Bradley
, J. Ingle
, T. Aihara
, J. Bliss
, F. Boccardo
, A. Coates
, R. C. Coombes
, J. Cuzick
, P. Dubsky
, M. Gnant
, M. Kaufmann
, L. Kilburn
, F. Perrone
, D. Rea
, B. Thuerlimann
, C. van de Velde
, H. Pan
, R. Peto

C. Davies, R. Gray, M. Baum, A. Buzdar, I. Sestak, C. Markopoulos, C. Fesl, R. Jakesz, M. Colleoni, R. Gelber, M. Regan, G. von Minckwitz, C. Snowdon, P. Goss, Early Breast Cancer Trailists’ Collaborative Group EBCTCG, Petrus Hupperets

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background the optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.

Original language	English
Pages (from-to)	1341-1352
Number of pages	12
Journal	Lancet
Volume	386
Issue number	10001
DOIs	https://doi.org/10.1016/S0140-6736(15)61074-1
Publication status	Published - 3 Oct 2015

Access to Document

10.1016/S0140-6736(15)61074-1Licence: CC BY

Cite this

Dowsett, M., Forbes, J. F., Bradley, R., Ingle, J., Aihara, T., Bliss, J., Boccardo, F., Coates, A., Coombes, R. C., Cuzick, J., Dubsky, P., Gnant, M., Kaufmann, M., Kilburn, L., Perrone, F., Rea, D., Thuerlimann, B., van de Velde, C., Pan, H., ... Hupperets, P. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet, 386(10001), 1341-1352. https://doi.org/10.1016/S0140-6736(15)61074-1

@article{12f2c3af87004da8a37c0aed17c16ca6,

title = "Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials",

abstract = "Background the optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.",

author = "M. Dowsett and Forbes, \{J. F.\} and R. Bradley and J. Ingle and T. Aihara and J. Bliss and F. Boccardo and A. Coates and Coombes, \{R. C.\} and J. Cuzick and P. Dubsky and M. Gnant and M. Kaufmann and L. Kilburn and F. Perrone and D. Rea and B. Thuerlimann and \{van de Velde\}, C. and H. Pan and R. Peto and C. Davies and R. Gray and M. Baum and A. Buzdar and I. Sestak and C. Markopoulos and C. Fesl and R. Jakesz and M. Colleoni and R. Gelber and M. Regan and \{von Minckwitz\}, G. and C. Snowdon and P. Goss and \{Early Breast Cancer Trailists{\textquoteright} Collaborative Group EBCTCG\} and Petrus Hupperets",

year = "2015",

month = oct,

day = "3",

doi = "10.1016/S0140-6736(15)61074-1",

language = "English",

volume = "386",

pages = "1341--1352",

journal = "Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10001",

}

Dowsett, M, Forbes, JF, Bradley, R, Ingle, J, Aihara, T, Bliss, J, Boccardo, F, Coates, A, Coombes, RC, Cuzick, J, Dubsky, P, Gnant, M, Kaufmann, M, Kilburn, L, Perrone, F, Rea, D, Thuerlimann, B, van de Velde, C, Pan, H, Peto, R, Davies, C, Gray, R, Baum, M, Buzdar, A, Sestak, I, Markopoulos, C, Fesl, C, Jakesz, R, Colleoni, M, Gelber, R, Regan, M, von Minckwitz, G, Snowdon, C, Goss, P, Early Breast Cancer Trailists’ Collaborative Group EBCTCG & Hupperets, P 2015, 'Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials', Lancet, vol. 386, no. 10001, pp. 1341-1352. https://doi.org/10.1016/S0140-6736(15)61074-1

TY - JOUR

T1 - Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

AU - Dowsett, M.

AU - Forbes, J. F.

AU - Bradley, R.

AU - Ingle, J.

AU - Aihara, T.

AU - Bliss, J.

AU - Boccardo, F.

AU - Coates, A.

AU - Coombes, R. C.

AU - Cuzick, J.

AU - Dubsky, P.

AU - Gnant, M.

AU - Kaufmann, M.

AU - Kilburn, L.

AU - Perrone, F.

AU - Rea, D.

AU - Thuerlimann, B.

AU - van de Velde, C.

AU - Pan, H.

AU - Peto, R.

AU - Davies, C.

AU - Gray, R.

AU - Baum, M.

AU - Buzdar, A.

AU - Sestak, I.

AU - Markopoulos, C.

AU - Fesl, C.

AU - Jakesz, R.

AU - Colleoni, M.

AU - Gelber, R.

AU - Regan, M.

AU - von Minckwitz, G.

AU - Snowdon, C.

AU - Goss, P.

AU - Early Breast Cancer Trailists’ Collaborative Group EBCTCG

AU - Hupperets, Petrus

PY - 2015/10/3

Y1 - 2015/10/3

N2 - Background the optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.

AB - Background the optimal ways of using aromatase inhibitors or tamoxifen as endocrine treatment for early breast cancer remains uncertain.

U2 - 10.1016/S0140-6736(15)61074-1

DO - 10.1016/S0140-6736(15)61074-1

M3 - Article

SN - 0140-6736

VL - 386

SP - 1341

EP - 1352

JO - Lancet

JF - Lancet

IS - 10001

ER -

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

Abstract

Access to Document

Fingerprint

Cite this